Takeda offers its employees a chance to participate in the event if they commit to raising at least $1,000 for CCFA. Employee interest in this event has steadily grown over the years, Brown explains, with 110 Takeda employees traveling to Napa this weekend to run, walk and jog over the 13.1 mile course or participate in the 5K event. CCFA expects hundreds of participants in the popular half marathon event. Last year, more than 600 Team Challenge runners and walkers from across the country crossed the picturesque finish line and raised millions to support groundbreaking research of Crohn's disease and ulcerative colitis.
The company and its employees expect to raise nearly $500,000 for CCFA, which will use the monies to further its mission of finding cures and improving the quality of life for patients living with IBD.
About Takeda Pharmaceuticals U.S.A., Inc.
Headquartered in Deerfield, IL as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502), Osaka, Japan, the Company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of R&D focus include central nervous system, cardiovascular and metabolic, gastroenterology, oncology, and vaccines.
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/takeda-aims-to-raise-500000-for-team-challenge-for-crohns--colitis-300299450.html
SOURCE Takeda Pharmaceuticals U.S.A., Inc.